The development of LOX/LOXLs-targeted therapeutic tools, however, has been hampered by the unavailability of their crystallographic structure and the fact that both increases and decreases of LOX/LOXLs underlie the development of different cardiovascular diseases that often coexist. Here, LOX is linked to cardiovascular disorder.